Ovarian Epithelial Cancer Clinical Trial
Official title:
A Phase I, Open, Randomized, Study to Investigate the Safety of Active Immunotherapy With Fully Mature, TERT-mRNA and Survivin - Peptide Double Loaded Dendritic Cells (DCs) in Subjects With Advanced Epithelial Ovarian Cancer, Enrolled in the Study Within Twelve Weeks After Completing Primary Therapy
The purpose of this study is to investigate the safety of the active immune therapy based on the reiterated injection of fully mature, TERT (Telomerase Reverse Transcriptase)-mRNA and Survivin-peptide double loaded DCs (Dendritic Cells) [Procure®] in patients with advanced ovarian cancer, enrolled into the study within twelve weeks after completing primary therapy.
This is an uncontrolled, randomized, parallel-group, open-label phase I trial in patients
with advanced epithelial ovarian cancer. Patients were randomized into treatment group A
with weekly administration versus treatment group B with bi-weekly administration.
Patients in both treatment groups received a maximum of eight injections administered one by
one once a week for eight times for treatment group A and once in a fortnight for eight
times for treatment group B.
The treatment was completed within seven weeks for Arm A and within 14 weeks for Arm B.
Independently of the treatment arm they had been assigned to, all the patients were followed
for a period covering a total of 12 or 19 weeks or until disease progression. Safety
parameters (primary objective) and efficacy parameters (secondary objective) were recorded.
Upon completion of the treatment, one follow-up visit took place at week 12 (group A, only)
or 19 (group B, only).
To protect the patients' safety, the first six patients were treated as described below:
- The first patient was hospitalized and kept under medical observation for 72h after
administration of the first and second dose of the investigational product;
- After an observational period of 3 days following the second dose of the first patient,
the second and the third patient were administered the first dose of the
investigational product, hospitalized and kept under medical observation for 72h. The
two patients were treated simultaneously or consecutively;
- After an observational period of 3 days after the second dose to the first three
patients, an interim safety report was sent to the Ethics Committee;
- Additionally the next three patients were hospitalized, administered their first dose
of the vaccine and kept under medical observation for 72h. The three patients were
treated simultaneously or consecutively.
15 evaluable patients (which were randomized to one of the two treatment groups in
equal numbers) 5 study sites in Austria and Hungary
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02096783 -
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
|
N/A | |
Recruiting |
NCT06404671 -
Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
|
N/A | |
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03220932 -
Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer
|
Phase 3 | |
Not yet recruiting |
NCT05937620 -
Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer
|
N/A | |
Completed |
NCT02039388 -
Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma
|
N/A | |
Completed |
NCT02107937 -
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
|
Phase 2 | |
Completed |
NCT02107950 -
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
|
Phase 2 | |
Completed |
NCT01806350 -
Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors
|
N/A | |
Recruiting |
NCT03349463 -
Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
|
Phase 4 | |
Completed |
NCT04823871 -
Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing
|
N/A | |
Completed |
NCT02518256 -
Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity
|
N/A | |
Active, not recruiting |
NCT03078400 -
Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer
|
Phase 1 | |
Completed |
NCT02489903 -
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
|
Phase 2 | |
Not yet recruiting |
NCT02435186 -
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
|
Phase 2 | |
Recruiting |
NCT04029909 -
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
|
Phase 1 | |
Recruiting |
NCT05498597 -
AMT-151 in Patients With Selected Advanced Solid Tumours
|
Phase 1 | |
Suspended |
NCT02742428 -
Preoperative Ascites Drainage Versus Standard Care for Patients With Advanced Ovarian Cancer
|
N/A | |
Active, not recruiting |
NCT02981901 -
Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France
|
||
Completed |
NCT02062697 -
Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.
|
N/A |